We have a culture that inspires intellectual curiosity and flexibility.
Counterpoint Global, one of our Active Fundamental Equity teams, seeks to make long-term investments in unique companies whose market value can increase significantly for underlying fundamental reasons. Their portfolios are typically concentrated and differentiated from their benchmarks. Counterpoint Global consists of 47 people, including 25 investors, four disruptive change researchers, two consilient researchers and two sustainability researchers. Counterpoint Global’s culture fosters collaboration, creativity, continued development, and differentiated thinking.
Strategies
| Strategy Name | Description | |
|---|---|---|
|
||
|
Invests primarily in established and emerging companies globally.
|
||
|
Invests primarily in established companies globally that benefit from efficient scale.
|
||
|
Invests primarily in established and emerging large cap companies in the United States.
|
||
|
Invests primarily in established and emerging companies globally.
|
||
|
Invests primarily in established and emerging small cap companies in the United States.
|
||
|
Invests primarily in established and emerging mid cap companies in the United States.
|
||
|
Invests primarily in established and emerging companies in the United States.
|
||
|
Invests primarily in established large cap companies in the United States.
|
||
|
Invests primarily in established companies in the United States that benefit from efficient scale.
|
||
|
||
|
Invests in high quality established and emerging companies located in Asia (excluding Japan) that the team believes are undervalued at the time of investment.
|
||
|
Invests primarily in high quality companies located or operating in developing or emerging market countries that the team believes are undervalued at the time of investment.
|
||
|
Invests primarily in high quality established and emerging companies located in Europe that the team believes are undervalued at the time of investment.
|
||
|
Invests globally in high quality established and emerging companies that the team believes are undervalued at the time of investment.
|
||
|
Invests internationally in high quality established companies that the team believes are undervalued at the time of investment.
|
||
|
Invests internationally in high quality established and emerging companies that the team believes are undervalued at the time of investment.
|
||
|
||
|
Invests primarily in companies with growing intrinsic value.
|
||
|
||
|
Invests primarily in companies principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare.
|
||
Insights
Subscribe to Counterpoint Global Insights - Consilient Observer
Submit
Thank you for subscribing to Counterpoint Global Insights – Consilient Observer.